Diagnostic Testing of STDs Market, By Test Type (Chlamydia, Gonorrhea, Syphilis, HIV, HPV+pap smear, HSV, and Chancroid), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023

Code : CMI3917

Pages :160

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Leading Companies

The major players operating in the global diagnostic testing of STDs market include Vela Diagnostics USA Inc., Roche Holdings AG, Alere, Inc., Becton Dickinson & Company, bioMerieux, Danaher Corporation (Beckman Coulter), Hologic, Inc., binx health, Chembio Diagnostics, Pinpoint Science Inc., and bioLytical Laboratories.

Global Diagnostic Testing of STDs Market: Key Developments

Initiatives by government organizations to provide testing kits in cost effective manner can drive the growth of the global diagnostic testing of STDs market. For instance, in January 2023, on the occasion of Cervical Cancer Awareness Month, United Nations International Children's Emergency Fund (UNICEF) launched the Cervical Cancer Toolkit, a comprehensive tool for combating the disease. This toolkit contains the novel HPV vaccines, high-performing diagnostic tests for HPV, and portable devices for pre-cervical cancer treatment which are very well-suited for low-resource settings.

On December 17, 2021, Becton, Dickinson and Company, a U.S.-based medical technology company, announced it has expanded the BD COR System to include a new MX instrument for high-throughput molecular testing for infectious diseases. The new instrument and its first test for sexually transmitted infections have the European Conformity (CE) marked to the in-vitro diagnostic directive 98/79/EC. It includes PX instrument that can prepare diagnostic samples by automating appropriate pre-analytical processing steps and a GX instrument that can leverage the BD Onclarity HPV Assay with extended genotyping to screen for HPV infections.

On December 14, 2021, Quest Diagnostics Inc., a U.S.-based diagnostics information service provider, announced it has acquired all assets of Labtech Diagnostics, U.S. based diagnostics service provider. With this acquisition, Quest Diagnostics Inc. got access to diagnostic innovation and more communities in southeast region of U.S. This will enable physicians to get access to diagnostic services directly from Quest Diagnostics Inc., through its Cleveland HeartLab cardiometabolic center of excellence and other laboratories in the U.S.